Literature DB >> 7533868

Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies.

J Aubin1, F Davi, F Nguyen-Salomon, D Leboeuf, C Debert, M Taher, F Valensi, D Canioni, N Brousse, B Varet.   

Abstract

PCR amplification of IgH gene V-D-J junctional variability (IgH PCR) is increasingly replacing Southern analysis for the detection of clonal lymphoid populations in cases presenting diagnostic difficulties. In order to determine the most efficient strategy, we have compared three known methods, using consensus primers against the VH FR3 or FR2 (FR256) regions, or a mix of six primers against the FR1 region (FR1f), with a new approach using a consensus primer against FR1 (FR1c), never previously described for diagnostic purposes, on DNA from 89 monoclonal B-cell proliferations (16 ALL, 28 CLL/PLL, 15 myelomas, 30 NHL). We obtained a detection rate of 70% for FR3, 64% for FR1f and 77% and 78% for FR256 and FR1c, respectively. Polyclonal lymphocytes and mature T cell malignancies tested negative for all systems. Differences in the detection rate were related not only to the choice of VH primer but also the JH primer(s) used and the pathological subtype. All strategies led to adequate detection of leukaemic DNA, whereas the detection rate in myeloma varied between strategies from 47 to 80% and that of follicular lymphoma from 13 to 63%. The lowest detection rates were observed in follicular lymphoma and in mature CD5 negative proliferations, reflecting the probable correlation between somatic mutation and PCR false-negativity. The combined use of FR1c and FR256 allowed detection in at least one system of 92% of cases overall and at least 75% in all pathological subtypes, thus providing a simple, reliable and rapid non-radioactive system for the detection of B cell clonality.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533868

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  24 in total

1.  Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.

Authors:  Roberto Marasca; Rossana Maffei; Monica Morselli; Patrizia Zucchini; Ilaria Castelli; Silvia Martinelli; Marcella Fontana; Sara Ravanetti; Monica Curotti; Giovanna Leonardi; Katia Cagossi; Giovanni Partesotti; Giuseppe Torelli
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

2.  Consensus JH gene probes with conjugated 3'-minor groove binder for monitoring minimal residual disease in acute lymphoblastic leukemia.

Authors:  Michihiro Uchiyama; Chihaya Maesawa; Akiko Yashima-Abo; Mitsu Tarusawa; Mikiya Endo; Waka Sugawara; Shoichi Chida; Shima Onodera; Yasuhiko Tsukushi; Yoji Ishida; Shigeru Tsuchiya; Tomoyuki Masuda
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

3.  Role of polymerase chain reaction and immunocytochemistry in the cytological assessment of lymphoid proliferations.

Authors:  L Venkatraman; M A Catherwood; A Patterson; T F Lioe; W G McCluggage; N H Anderson
Journal:  J Clin Pathol       Date:  2006-03-13       Impact factor: 3.411

4.  Biologically-generated primer for PCR: PCR primer of unknown sequence.

Authors:  C Bindon; J Martindale; C Mitchell
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

5.  Establishment of a novel B cell clonality analysis using single-strand conformation polymorphism of immunoglobulin light chain messenger signals.

Authors:  S Shiokawa; J Nishimura; K Ohshima; N Uike; K Yamamoto
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

6.  Assessment of IgH PCR strategies in multiple myeloma.

Authors:  R G Owen; R J Johnson; A C Rawstron; P A Evans; A Jack; G M Smith; J A Child; G J Morgan
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

7.  The DG75 B-cell lymphoma line exhibits biclonal immunoglobulin gene rearrangement.

Authors:  Zongli Qi; Yuan Li; Jun Hu; Hua Guo; Xiangrong Zhao; Guanghua Wang; Jinwei Gao; Qiaoxia Hu
Journal:  Biomed Rep       Date:  2012-10-12

8.  Consensus primers for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell lymphomas.

Authors:  M Uchiyama; C Maesawa; A Yashima; T Itabashi; Y Ishida; T Masuda; T Maesawa
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

9.  Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia.

Authors:  Sabrina Uhrmacher; Felix Erdfelder; Karl-Anton Kreuzer
Journal:  Adv Hematol       Date:  2010-09-20

10.  Outpatient-based therapy of oral fludarabine and subcutaneous alemtuzumab for asian patients with relapsed/refractory chronic lymphocytic leukemia.

Authors:  William Y K Hwang; Claire Dearden; Yvonne S M Loh; Yeh C Linn; Sim L Tien; Gerrard K H Teoh; Gee F How; Kee K Heng; Yeow T Goh; Lai H Lee
Journal:  Adv Hematol       Date:  2008-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.